Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 495 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 0.9% normal saline injection Clear all
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial

NCT03508830
View directory record Official record
Conditions
Thoracic Diseases, Postoperative Pain, Opioid Use
Interventions
Liposomal bupivacaine, Bupivacaine Injection
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 23, 2026, 4:20 AM EDT
Recruiting Early Phase 1 Interventional

NSAIDs Stent Study

NCT03638999
View directory record Official record
Conditions
Ureteral Stent Placement, Kidney Stone
Interventions
Ketorolac Trometamol 30Mg/1mL Injection, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 23, 2026, 4:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers of Trained Immunity Following MMR Vaccination

NCT04646239
View directory record Official record
Conditions
Covid19
Interventions
Heterologous stimuli, Neutralization assay
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 23, 2026, 4:20 AM EDT
Terminated Phase 2 Interventional Results available

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

NCT03146403
View directory record Official record
Conditions
Genital Herpes, HSV-2 Infection
Interventions
GEN-003, Matrix-M2, 0.9% normal saline
Biological · Other
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 23, 2026, 4:20 AM EDT
Terminated Phase 1Phase 2 Interventional

Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

NCT03117166
View directory record Official record
Conditions
Pain
Interventions
lidocaine, Placebo
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT06375512
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ Vaccine (IN001), Placebo, Shingrix
Biological
Lead sponsor
Shenzhen Shenxin Biotechnology Co., Ltd
Industry
Eligibility
50 Years to 69 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 23, 2026, 4:20 AM EDT
Active, not recruiting Early Phase 1 Interventional

Role of Multimodal Analgesia in Decreasing Perioperative Pain in Tibial Plateau Fractures

NCT05037812
View directory record Official record
Conditions
Tibial Plateau Fractures
Interventions
Saline injection, Multimodal injections
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 79 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

NCT07473752
View directory record Official record
Conditions
Phase 1 First-in-human Study Involving Healthy Subjects
Interventions
TNX-1500, Placebo: USP 0.9% sterile saline for injection, Keyhole Limpet Hemocyanin (KLH)
Drug · Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

NCT03395704
View directory record Official record
Conditions
Hereditary Hemochromatosis
Interventions
LJPC-401, Placebo
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
18
States / cities
North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 23, 2026, 4:20 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Trial of Levator Muscle Blocks Following Posterior Colporrhaphy Surgery to Reduce Post-operative Pain.

NCT03067168
View directory record Official record
Conditions
Post Operative Pain
Interventions
Bupivacaine, normal saline 0.9%
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

NCT02452372
View directory record Official record
Conditions
Acute Intermittent Porphyria
Interventions
givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

NCT01188564
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
rhC1INH, Placebo (Saline)
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
13 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Clofarabine Bone Marrow Cytoreduction

NCT00724009
View directory record Official record
Conditions
Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure

NCT01544998
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Nesiritide, Tadalafil, Placebo, Saline load
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 23, 2026, 4:20 AM EDT
Withdrawn Phase 4 Interventional

ABC Blocks for Cardiac Surgery

NCT05589363
View directory record Official record
Conditions
Pain
Interventions
ABC block with bupivacaine/liposomal bupivacaine, ABC block with saline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

NCT05089084
View directory record Official record
Conditions
Familial Chylomicronemia
Interventions
Plozasiran, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Boca Raton, Florida • Suwanee, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of TT301 on Cytokine Levels Post Endotoxin Challenge

NCT01357421
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
TT301, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

NCT04123561
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TLC599, DSP, Normal Saline
Drug · Other
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
40 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

The Effect of RNS60 on ALS Biomarkers

NCT03456882
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
RNS60
Drug
Lead sponsor
Mario Negri Institute for Pharmacological Research
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 1 Interventional

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT01134341
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions
Pralatrexate Injection, Bexarotene Capsules, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 23, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

NCT01221441
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
TissueGene-C, Normal Saline
Biological · Drug
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Pinellas Park, Florida • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 23, 2026, 4:20 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

NCT05731440
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 23, 2026, 4:20 AM EDT
Recruiting Phase 2 Interventional

Antibiotic Tumescent For Chronic Wounds

NCT06327113
View directory record Official record
Conditions
Non-healing Wound
Interventions
CeFAZolin Injectable Solution
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 23, 2026, 4:20 AM EDT